-+ 0.00%
-+ 0.00%
-+ 0.00%

Keymed Biosciences says Phase II trial of CM512 meets endpoints in chronic rhinosinusitis with nasal polyps

PUBT·08/10/2026 00:01:03
Listen to the news
Keymed Biosciences says Phase II trial of CM512 meets endpoints in chronic rhinosinusitis with nasal polyps
  • Keymed Biosciences reported its Phase II trial of CM512 for chronic rhinosinusitis with nasal polyps met all study endpoints.
  • Patients showed rapid symptom improvement, sustained benefits through the end of the study, with consistent effects across dose groups.
  • The safety profile looked favorable, with tolerability similar to placebo and no serious adverse events reported in CM512 arms.
  • Detailed results have not been presented yet; they are slated for future release in international journals or conferences.
  • The company is starting Phase III, selecting 300 mg every 24 weeks as the planned dosing regimen.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keymed Biosciences Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260810-12278065), on August 10, 2026, and is solely responsible for the information contained therein.